secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2026-08-06T12:30:16+00:00
Accession:  0001193125-26-336886
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q2 net loss $79.1M ($0.90/shr); adds $500M ATM capacity
-------------------------------------------------------------------

- Net loss of $79.1M ($0.90 per share) vs $41.4M ($0.54) in Q2 2025; R&D $54.7M, G&A $29.0M.
- Cash, equivalents and marketable securities $1.0B as of June 30, 2026, down from $1.1B on March 31, 2026.
- Filed Amendment No. 2 to Prospectus to increase ATM shares by $500M (previously sold ~$550M).
- PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk NMIBC expected near-term.
- BLA submission for HR BCG-unresponsive NMIBC with CIS expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/0001193125-26-336886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer